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INTRODUCTION
Catatonia is a syndrome, comprised of such symptoms as mo-
tor immobility, excessive motor activity, extreme negativism, 
and stereotyped movements. It mainly occurs in primary 
mood or psychotic illness and in medical and surgical condi-
tions such as neoplasms, encephalitis, head traumas, diabetes, 
and metabolic disorders.
1 Since Kahlbaum coined the name 
“vesania katatonica” in 1874, Kraepelin began using “catatonia” 
for a schizophrenia subtype in 1899, and Kleist explained cata-
tonia as a kind of extrapyramidal disorder related to the basal 
ganglia in 1943.
2 Recently, Kahlbaum explained catatonia as a 
disease, inferring this concept from various studies and expe-
riences showed patients with catatonia symptoms commonly re-
sponded favorably to lorazepam and electroconvulsive therapy 
(ECT).
3 However, no one has yet clearly explained the nature and 
neurobiological basis of catatonia.
4
Neuroleptic malignant syndrome (NMS) is a rare syndrome, 
observed in only 0.2% of psychiatric patients,
5 and patients typ-
ically show symptoms such as an altered mental state, muscle 
rigidity, tremor, tachycardia, hyperpyrexia, leucocytosis, and el-
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evated serum creatine kinase.
6 Any antipsychotic drug, includ-
ing the atypical ones, can cause NMS.
7
Recently, several researchers have reported studies on anti-
psychotic-induced catatonia and the association between 
catatonia and NMS,
2,8-10 but none were from Korea. Here, we 
report a case of catatonia and NMS correlated with the admin-
istration of an atypical antipsychotic drug. 
CASE
A 20-year-old female with no neuropsychiatric history 
gradually became restless around July 2009. She complained 
of anxiety, cried often, and could not sleep. Several days later, 
the patient experienced auditory hallucination, she screamed 
in her home, “I cannot kill mom! I should die!” and attempted 
to jump out a window. When her mother stopped the patient, 
she ran to the kitchen and picked up a knife. From that time 
on, she talked continuously to herself. As these symptoms con-
tinued, she was admitted to the psychiatric hospital with a im-
pression of psychotic disorder not otherwise specified (NOS). 
She received olanzapine 10 mg/daily for 3 days, but her symp-
toms did not change, and side-effect symptoms appeared such 
as sedation, drooling and dysarthria. Thus, the psychiatrist 
switched her prescription to risperidone 4 mg/daily. After 2 
days of risperidone, the patient spent most of her time on the 
bed without any appropriate communication. As she began sh-
owing such behaviors as mumbling and chewing her lips, the 
psychiatrist changed her medication to aripiprazole 10 mg/dai-
ly. On the 4th day of aripiprazole treatment, she showed almost 
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no response to verbal stimuli or light pain. As eating and reliev-
ing herself unaided were beyond the patient’s abilities, a naso-
gastric tube was inserted. Since she had a mild fever, she under-
went hematological tests and a chest X-ray, but these revealed 
no particular abnormal findings. Despite receiving continuous 
antipsychotic medication, the patient showed no improvement. 
Therefore, she was transferred to our university hospital for fur-
ther evaluation.
Upon her admission, the patient’s symptoms were continued. 
Moreover, as she showed intermittent rigidity, she gnawed her 
teeth and bit her lips, she lost her 4 teeth. We performed a brain 
magnetic resonance imaging (MRI), spinal fluid tap, and elec-
troencephalogram (EEG), but the brain MRI and the spinal 
fluid revealed no particular findings. In EEGs of the patient, we 
observed a slow wave in the frontal lobe. Due to the patient’s fe-
ver, we administered antibiotics, but the fever did not recede. 
Findings from the department of internal medicine showed no 
particular active lung lesion on the chest X-ray and suspicious 
lesion was focal consolidation finding which would be found 
on chest computer tomography (CT) only. Microorganism was 
not cultivated on the blood microorganism study and any oth-
er microorganism was not cultivated except normal flora on 
the sputum microorganism study. Consequently, because the 
lesion of the chest was small and minor, the medical doctor did 
not consider the lesion to be causing the patient’s continuous 
high fever. Her blood pressure remained in a relatively normal 
range, and her electrocardiogram (ECG) did not show any par-
ticular findings except atrial tachycardia. On her 2
nd day in our 
hospital, her blood oxygen saturation suddenly dropped to 
67%, so we inserted a tracheal tube and placed her on a venti-
lator. The medical doctor believed a temporary laryngospasm 
had caused the oxygen saturation decrease. The reason of sus-
pecting of laryngospasm was that the patient intermittently sh-
owed excessive motor activity, rigidity and, also dystonia on 
buccopharyngeal part, and that she did not have lesion that 
would lead to sudden dyspnea on chest X-ray and chest CT fin-
ding at that time. A chest CT scan did not show any particular 
change from the previous one. And considering that the patient 
did not have a history of asthma, it is highly possible that the 
patient has episodic laryngospasm. Despite continuous medi-
cation with antibiotics and antipyretics, her 38-39°C fever and 
100-150 heart rate continued. In hematological tests, the patient’s 
leukocyte count increased to 13,700, and her Creatine Phos-
phate Kinase (CPK) increased to 558. When we removed the 
respirator on her 14
th day in Intensive Care Unit (ICU), her res-
piration was stable, but the fever did not recede. On her 18
th 
day in ICU, the fever still continued, but the medical doctor jud-
ged that no further medical treatment was necessary. There-
fore, the patient was transferred to the Psychiatric Ward.
On her 1st day in this ward, the patient stayed in the bed all 
day and showed only non-specific responses to verbal stimuli. 
She could not respond appropriately to questions, and her body 
became rigid or writhed several times a day. In hematological 
tests, her leukocyte count decreased to 11,940 than before, CPK 
also decreased to 341 than before, aspartase aminotransferase/
alanine aminotransferase ratio to 61/76, and serum iron level de-
creased to 30 μg/dL. On her 9th day in the Psychiatric Ward, 
the patient’s fever fell, and her heart rate became stable, so we 
decided to administer ECT treatment. After 3rd ECT treatments, 
the patient could have a short conversation with her family. For 
maintenance treatment, the patient received olanzapine (zy-
prexa zydis) 5 mg/daily, which melts on the tongue, from the 5th 
ECT. As she could speak her thought and feelings, she reported 
that she had some psychotic symptoms such as auditory hallu-
cination, delusion of possession before admission in the psychi-
atric hospital. The patient stated she had been arrested by an 
evil spirit, or an evil spirit entered her at that time. After the 10th 
ECT, the patient could get up, walk, and do daily routines little 
by little. The patient underwent ECT total 16 times, and after 
two months of inpatient treatment, the patient did not show any 
psychotic symptoms. She has currently been receiving outpatient 
treatment for 9 months without complaining of any psychotic 
symptoms. 
DISCUSSION
Diagnostic and Statistical Manual of Mental Disorders, 4
th 
edition, Text Revision (DSM-IV-TR) classifies catatonia into the 
sub-groups of schizophrenia, bipolar disorder, major depressive 
disorder, and general medical condition.
11 Several recent stud-
ies, however, point out an association between catatonia and 
both neuroleptic use and pervasive developmental disorder.
12 
The researchers attempt particularly to define catatonia due to 
neuroleptics by first classifying the causes of catatonia as spon-
taneous, psychogenic, or neuroleptic.
13,14 For this case, the sy-
mptoms of catatonia were not apparent at the onset of symp-
toms, but, rather, they developed rapidly after she received an 
antipsychotic drug. Any medicine except atypical antipsychot-
ics was not used to the patient in the psychiatric hospital and 
our university hospital, and only lorazepam 2-4 mg intramus-
cular injection was intermittently used to improve her rigidity 
and irritability. In this case, we cannot assert definitely that the 
use of an antipsychotic drug caused her catatonia, but we at least 
can assume that the antipsychotic drug may be associated with 
her catatonia. Our patient showed the catatonia symptoms of 
extreme mutism, rigidity, negativism, and stereotyped move-
ment after using antipsychotic drug, and later showed mental 
stupor and a high fever, leading us to suspect NMS. According 
to recent reports, NMS due to an atypical antipsychotic drug 
differs from the characteristic symptoms of NMS due to a typi-176  Psychiatry Investig 2011;8:174-177
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cal antipsychotic drug, in that it occurs acutely, within a few 
days of the patient beginning the medication, and may show an 
atypical symptom pattern, for the muscle rigidity, consciousness 
alteration, and CPK increase do not appear clearly.
15-20 For this 
reason, Nopoulos et al.
21 suggested that this should be called 
“atypical NMS” or “pseudo-neuroleptic malignant syndrome,” 
to distinguish it. There have already been many case reports on 
patients developing NMS from lethal catatonia,
22 and a number 
of studies reported similarities between NMS and catatonia 
in terms of their clinical characteristics,
23,24 biological character-
istics,
7,25-28 and treatment response patterns.
29-32 In particular, 
many authors maintain that lethal catatonia cannot be clinical-
ly separated from NMS.
8,23,24 With regard to treatment respons-
es, 40% of NMS patients responded to benzodiazepine,
33 and 
Lee’s study classified NMS patients into either a catatonic type, 
which showed catatonia symptoms and responded to benzodi-
azepine during the NMS episode, and a non-catatonic type that 
did not do so.
22 Accordingly, some researchers regard catatonia 
that responds to benzodiazepine as an NMS subtype.
31
Due to such characteristics, some researchers consider cata-
tonia and NMS to be disorders along a single spectrum,
8,23 and 
there are even such reports as that of Tsai et al.,
14 stating NMS 
and catatonia are in the same “neuroleptic toxicity spectrum” 
category, and of Mathews and Aderibigbe, regarding NMS as a 
severe subtype of catatonia, classified as “drug-induced hyperther-
mic catatonia.”
34 And some researchers regarded catatonia, extra-
pyramidal symptoms (EPS), agitation, and low serum iron level 
as risk factors of NMS.
2,25,35 
Summing up, the case in this study does not constitute clear 
evidence that antipsychotic drugs are a direct cause of catatonia 
symptoms, but, inferring from previous reports, we can at least 
presume antipsychotic drugs are associated with catatonia. Fur-
thermore, regarding the NMS occurring after the catatonia, we 
observed symptoms similar to recent case reports of NMS cau-
sed by an atypical antipsychotic drug. In our case, ECT made 
the great contribution to the patient’s rapid improvement. Giv-
en that, reported, morbidity and mortality may increase if cata-
tonia is not treated early,
36 ECT may be an effective treatment 
for a patient who does not respond to the usual medications, de-
pending on the patient’s condition. 
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